This article is more than 5 years old. Information may no longer be current.

Drug candidate for DME treatment to begin toxicology studies

Issue: May 25, 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

THR-149, a plasma kallikrein inhibitor for the potential treatment of diabetic macular edema, has reached a milestone in its development and will start pivotal toxicology studies, according to a press release from ThromboGenics.

This is the final step for the bicyclic peptide candidate (Bicycle, Bicycle Therapeutics) before beginning clinical development, which is expected in early 2018, the release said.

ThromboGenics and Bicycle Therapeutics have an alliance under which ThromboGenics has a license for preclinical and clinical development of a specified drug candidate and commercialization of the product, while Bicycle Therapeutics receives development milestone payments and royalties on product sales.

“We believe that THR-149, a novel plasma kallikrein inhibitor, holds great promise for ophthalmology applications, expanding the range of treatment options available for people with diseases of the eye, particularly DME,” Patrik De Haes, MD, CEO of ThromboGenics, said in the release.